ASP1002 / Astellas - LARVOL DELTA

A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=798 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | N=210 ➔ 798 | Trial completion date: May 2028 ➔ May 2030 | Trial primary completion date: Apr 2028 ➔ Apr 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • BRAF • CLDN4 • HER-2 • MSI • PGR

A novel bispecific antibody targeting CD137 and CLDN4 for treating patients with solid tumors (SITC 2024) - P1 | "Conclusions These preclinical data support the clinical investigation of ASP1002 as a potential therapeutic antibody in patients with CLDN4-expressing cancers. ASP1002 is currently being evaluated in a Phase 1 clinical trial (NCT05719558) for the treatment of patients with metastatic or locally advanced solid tumors."

Clinical • IO biomarker • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CLDN4 • IFNG • IL2 • TNFRSF9

Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4. (ASCO 2024) - P1 | "The minimum number of responders needed to establish activity is 4 (NSCLC), 3 (CRC), and 7 (UC). Study enrollment is currently ongoing in the United States."

Clinical • IO biomarker • Metastases • P1 data • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • CLDN4 • TNFRSF9

A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=210 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=210 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=210 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • CLDN4 • ER • HER-2 • PGR

A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=210 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

Metastases • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • CLDN4 • ER • HER-2 • PGR